1. Home
  2. FTNT vs ARGX Comparison

FTNT vs ARGX Comparison

Compare FTNT & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortinet Inc.

FTNT

Fortinet Inc.

HOLD

Current Price

$81.62

Market Cap

56.1B

Sector

Technology

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$814.66

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTNT
ARGX
Founded
2000
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.1B
52.6B
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
FTNT
ARGX
Price
$81.62
$814.66
Analyst Decision
Hold
Strong Buy
Analyst Count
30
19
Target Price
$90.67
$979.22
AVG Volume (30 Days)
5.4M
353.9K
Earning Date
02-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
22.04
N/A
EPS
2.43
23.27
Revenue
$6,554,700,000.00
$3,683,281,000.00
Revenue This Year
$15.69
$91.44
Revenue Next Year
$11.25
$36.90
P/E Ratio
$31.94
$32.78
Revenue Growth
14.78
92.98
52 Week Low
$70.12
$510.06
52 Week High
$114.82
$934.62

Technical Indicators

Market Signals
Indicator
FTNT
ARGX
Relative Strength Index (RSI) 58.49 46.21
Support Level $73.55 $781.07
Resistance Level $78.33 $818.78
Average True Range (ATR) 1.95 24.70
MACD 0.24 3.46
Stochastic Oscillator 68.98 71.38

Price Performance

Historical Comparison
FTNT
ARGX

About FTNT Fortinet Inc.

Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: